ArticlePloS one2026
Mutual solubilization of rosiglitazone and ibuprofen: Investigation and mechanistic insight.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe report for the first time that co-dissolved rosiglitazone and ibuprofen mutually enhance their aqueous solubility; the study was designed to quantify this phenomenon and clarify its origin.
methodsSolubility was measured by HPLC. Fluorescence and FT-IR spectroscopy were used to probe molecular interactions, while classical molecular dynamics simulations provided atomistic insight.
resultsThe fluorescence intensity of the mixed solution was markedly lower than that of either drug alone, indicating ground-state complexation or close association. FT-IR spectra showed no new peaks, confirming the absence of a new chemical entity or distinct crystal phase. Simulations revealed that each drug increases the solvent-solute compatibility of the other; the resulting hetero-association hinders nucleation and crystal growth, raising apparent solubility. At 30-60 °C, rosiglitazone solubility rose from 60.4-79.9 to 69.2-92.4 μg/mL (+6-16%), while ibuprofen increased from 50.6-89.5 to 56.3-105.0 μg/mL (+11-27%), confirming mutual enhancement.
conclusionThe observed mutual solubilization is attributed to specific intermolecular interactions and enhanced solvent compatibility. These findings offer a simple, formulation-free strategy for improving the dissolution of poorly water-soluble drugs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.